Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center

Am J Kidney Dis. 2000 Dec;36(6):1183-92. doi: 10.1053/ajkd.2000.19833.


Fungal peritonitis causes significant morbidity and mortality for patients undergoing continuous ambulatory peritoneal dialysis (CAPD). We retrospectively reviewed 70 episodes of fungal peritonitis in a single center over the last 9 years in 896 CAPD patients. Seventy percent of the episodes of fungal peritonitis were caused by Candida species, among which 50% were Candida parapsilosis. As a result of fungal peritonitis, 44% of the patients died, whereas further peritoneal dialysis failed in 14%, requiring a change to long-term hemodialysis. Only 37% managed to continue CAPD. The remaining 5% either underwent transplantation or were lost to follow-up. We identified the factors associated with poor outcome, namely mortality and technique failure. The presence of abdominal pain, bowel obstruction, and a catheter remaining in situ were significantly associated with greater mortality. Abdominal pain, antibiotic use within 3 months before fungal peritonitis, and complication by bowel obstruction were associated with greater technique failure. In choosing antifungal agents with catheter removal, oral fluconazole alone appears equally as effective as combined oral fluconazole with 5-flucytosine for peritonitis caused by Candida species. For peritonitis caused by species other than Candida, the choice of antifungal therapy needs to be individualized, based on fungal species and sensitivities.

MeSH terms

  • Antifungal Agents / therapeutic use
  • Humans
  • Mycoses / drug therapy*
  • Mycoses / etiology*
  • Mycoses / mortality
  • Outcome Assessment, Health Care
  • Peritoneal Dialysis / adverse effects*
  • Peritoneal Dialysis / mortality
  • Peritonitis / drug therapy
  • Peritonitis / etiology*
  • Peritonitis / mortality
  • Prognosis
  • Risk Factors
  • Treatment Outcome


  • Antifungal Agents